Article from

A look at the psychoactive brew that brings users a spiritual payoff for their “work”
In a greenhouse at the University of Minnesota, Dennis McKenna walks past the cacao (chocolate) and the Punica (pomegranate), and strides straight to the back corner, where the vines of the plant Banisteriopsis have twisted around each other — and nearby electrical cords — to reach the room’s rafters.

“There’s also a problem that the ‘normal’ ranges for one
laboratory may be decidedly different than they are for another
laboratory,” says Ronald Swerdloff, chief endocrinologist at Harbor
UCLA Medical Center in California and LA Biomed Inv.
Testosterone supplements promise men a butch boost of resurrected
libido, energy and mood. But there’s a better way to restore

“REDUCED sex drive? Decreased energy? Unwanted mood or body changes?
Is it low testosterone?”

Kythera Biopharmaceuticals’ new drug application (NDA) for its ATX-101, a submental contouring injectable drug, has been accepted for filing by the US Food and Drug Administration (FDA).

According to Kythera Biopharmaceuticals, the ATX-101 NDA will be subject to a standard review and will have a prescription drug user fee act (PDUFA) action date of 13 May 2015. The company submitted the NDA in May 2014.

The FDA’s Division of Dermatology and Dental Products is also planning to hold an Advisory Committee meeting on the company’s ATX-101 application during the review.

Investigator(s): The Lundquist Institute

Managing diabetes is a year-round challenge for anyone living with the disease. The challenge is even greater for underserved and uninsured people who often don’t have easy access to the care they need to manage their diabetes.

Their inability to effectively manage their diabetes puts them at significantly higher risk for long-term complications, including kidney failure, amputations and blindness.